Quantcast
Home > Quotes > VYGR

Voyager Therapeutics, Inc. Common Stock (VYGR) Quote & Summary Data

VYGR 
$10.69
*  
0.20
1.84%
Get VYGR Alerts
*Delayed - data as of Feb. 21, 2019 14:49 ET  -  Find a broker to begin trading VYGR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VYGR Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 10.68 / $ 10.70
1 Year Target
26
Today's High / Low
$ 11 / $ 10.51
Share Volume
100,975
50 Day Avg. Daily Volume
444,880
Previous Close
$ 10.89
52 Week High / Low
$ 31.91 / $ 7.76
Market Cap
348,032,983
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.46
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.83

Intraday Chart

Shares Traded

Share Volume:
100,975
50 Day Avg. Daily Volume:
444,880

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.46

Trading Range

The current last sale of $10.69 is 37.76% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 11 $ 31.91
 Low: $ 10.51 $ 7.76

Company Description (as filed with the SEC)

We are a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. We focus on neurological diseases where we believe an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. We have built a product engine, that we believe positions us to be the leading company at the intersection of AAV gene therapy and severe neurological disease. Our product engine enables us to engineer, optimize, manufacture and deliver our AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Additionally, we are working to identify novel AAV capsids, which are the outer viral protein shells that enclose the genetic material of the virus payload.  ... More ...  


Risk Grade

Where does VYGR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 10.88
Open Date:
Feb. 21, 2019
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info